reports
Biosyent Inc: 1 director
Two Directors at Biosyent Inc sold 301,137 shares at between 7.700CAD and 11.450CAD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...
BioSyent Announces Launch of New FeraMAX® Pd Powder 15
BioSyent Announces Launch of New FeraMAX® Pd Powder 15 MISSISSAUGA, Ontario, Oct. 19, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce the launch of FeraMAX® Pd Powder 15 by its subsidiary, BioSyent Pharma Inc., in Canada. FeraMAX® Pd Powder 15 is the second product incorporating Polydextrose-Iron Complex (PDIC), a patented oral iron supplement delivery system. In November 2020, BioSyent Pharma Inc. launched FeraMAX® Pd Therapeutic 150, the first product using the PDIC formulation in Canada. Together, these transitions to the p...
BioSyent annonce le lancement du nouveau FeraMAX (MD) Pd Poudre 15
BioSyent annonce le lancement du nouveau FeraMAX (MD) Pd Poudre 15 MISSISSAUGA, Ontario, 19 oct. 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent »,« la Société », Bourse de croissance TSX : RX) a le plaisir d’annoncer le lancement de FeraMAXMD Pd Poudre 15 par sa filiale, BioSyent Pharma Inc, au Canada. FeraMAXMD Pd Poudre 15 est le deuxième produit intégrant le complexe polydextrose-fer (CPDF), un système breveté de supplémentation en fer par voie orale. En novembre 2020, BioSyent Pharma Inc. a lancé FeraMAXMD Pd Thérapeutique 150, le premier produit utilisant la formulation CPDF au C...
BioSyent Releases Q2 and H1 2021 Financial Results
BioSyent Releases Q2 and H1 2021 Financial Results MISSISSAUGA, Ontario, Aug. 25, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and six months ended June 30, 2021. Key highlights include: Second quarter (Q2) 2021 Net Revenues of $7,289,254 increased by 53% versus Q2 2020First half (H1) 2021 Net Revenues of $14,709,143 increased by 36% versus H1 2020Record quarterly Canadian Pharmaceutical Net Revenues in Q2 2021 of $6,670,322 increased by 51% versus Q2 2020H1 2021 Canadian Pharmaceutical Net Revenues of $12,904,085...
BioSyent Signs Exclusive Technology Agreement
BioSyent Signs Exclusive Technology Agreement MISSISSAUGA, Ontario, July 13, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an agreement to license a unique technology application to support better treatment outcomes for patients with iron deficiencies in Canada and BioSyent’s international markets. “As a market leader in the treatment and prevention of iron deficiency and iron deficiency anemia with our FeraMAX® brand, we are familiar with the challenges that patients and their healt...
BioSyent Releases Financial Results for Q1 2021
BioSyent Releases Financial Results for Q1 2021 MISSISSAUGA, Ontario, May 27, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months ended March 31, 2021. Key highlights include: Record first quarter (Q1) 2021 Net Revenues of $7,419,889 increased by 22% versus Q1 2020Q1 2021 Canadian Pharmaceutical Net Revenues of $6,233,763 increased by 5% versus Q1 2020Q1 2021 International Pharmaceutical Net Revenues of $1,140,279 increased by 1,578% versus Q1 2020Q1 2021 EBITDA1 of $2,359,085 increased by 18% versus Q1 2020...
BioSyent Schedules Q1 2021 Earnings Release for May 27, 2021
BioSyent Schedules Q1 2021 Earnings Release for May 27, 2021 MISSISSAUGA, Ontario, May 20, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2021 on Thursday, May 27, 2021 at 8:00am EDT. A presentation on the Company’s first quarter 2021 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-o...
FeraMAX(MD) est le 1er choix de supplément de fer recommandé par les p...
FeraMAX(MD) est le 1er choix de supplément de fer recommandé par les pharmaciens et les médecins canadiens pour la sixième année consécutive MISSISSAUGA, Ontario, 05 mai 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent », Bourse de croissance TSX : RX) a le plaisir d’annoncer que pour la sixième année consécutive, FeraMAXMD a été désigné comme le 1er choix de marque de supplément de fer recommandée dans un sondage national mené auprès de médecins et de pharmaciens canadiens. Le sondage sur les recommandations en matière de médicaments en vente libre a été mené par EnsembleIQ, Research,...
FeraMAX® Named #1 Recommended Iron Supplement by National Pharmacists ...
FeraMAX® Named #1 Recommended Iron Supplement by National Pharmacists and Physicians for Sixth Consecutive Year MISSISSAUGA, Ontario, May 03, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that for the sixth consecutive year, FeraMAX® has been named the #1 recommended iron supplement brand in a national survey of Canadian physicians and pharmacists. The 2021 OTC Recommendations Survey was conducted by EnsembleIQ, Research, Insights and Innovation team and the following publications and websites: Pharmacy Practice + Business, The Medical Po...
BioSyent to Present at 2021 Bloom Burton & Co. Healthcare Investor Con...
BioSyent to Present at 2021 Bloom Burton & Co. Healthcare Investor Conference MISSISSAUGA, Ontario, April 14, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming Bloom Burton & Co. Healthcare Investor Conference. The conference will be held virtually on Tuesday, April 20 and Wednesday, April 21, 2021 between 8:30 am and 5:00 pm ET. Mr. René Goehrum, President and CEO of BioSyent, will present to investors an overview of BioSyent’s business and corporate activities on April 21 at 11:00 am. Mr. Goehrum wil...
BioSyent Announces Grant of Restricted Share Units
BioSyent Announces Grant of Restricted Share Units MISSISSAUGA, Ontario, March 19, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 67,252 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the Company’s Restricted Share Unit Plan (the “RSU Plan”). These RSUs will fully vest within three years on the third anniversary of the applicable grant date. About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symb...
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2...
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2020 MISSISSAUGA, Ontario, March 17, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and twelve months ended December 31, 2020. Key highlights include: Fourth quarter (Q4) 2020 Net Revenues of $5,726,328 increased by 3% versus Q4 2019Full year (FY) 2020 Net Revenues of $22,332,168 increased by 4% versus FY 2019Q4 2020 Canadian Pharmaceutical Net Revenues of $5,395,431 increased by 7% versus Q4 2019FY 2020 Canadian Pharmaceutical Net Revenu...
BioSyent Schedules Q4 and Full Year 2020 Earnings Release for March 17...
BioSyent Schedules Q4 and Full Year 2020 Earnings Release for March 17, 2021 MISSISSAUGA, Ontario, March 11, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2020 on Wednesday, March 17, 2021. A presentation on the Company’s fourth quarter and full year 2020 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange under the trading sym...
BioSyent Launches Combogesic®, First-Ever Acetaminophen + Ibuprofen Co...
BioSyent Launches Combogesic®, First-Ever Acetaminophen + Ibuprofen Combination Tablet in Canada Now Available Canadians have a new pain relief option MISSISSAUGA, Ontario, Dec. 16, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the first shipments of Combogesic® to Canadian wholesalers. Combogesic® is the first fixed-dose combination of acetaminophen and ibuprofen in a single tablet in Canada and is indicated for the short-term management of mild to moderate acute pain a...
BioSyent Announces Renewal of Normal Course Issuer Bid
BioSyent Announces Renewal of Normal Course Issuer Bid MISSISSAUGA, Ontario, Dec. 11, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the Company’s Notice of Intention to Make a Normal Course Issuer Bid (the “NCIB”). Pursuant to the NCIB, BioSyent may purchase up to 950,000 of its common shares (“Shares”) over a 12-month period, representing approximately 7.42% of the Shares outstanding as of December 11, 2020. The NCIB will commence on December 17, 2020 and terminate on Dece...
BioSyent Releases Financial Results for Third Quarter and First Nine M...
BioSyent Releases Financial Results for Third Quarter and First Nine Months of 2020 MISSISSAUGA, Ontario, Nov. 26, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and nine months ended September 30, 2020. Key highlights include: Third quarter (Q3) 2020 Net Revenues of $5,771,739 decreased by 7% versus Q3 2019First nine months (YTD) 2020 Net Revenues of $16,605,840 increased by 5% versus YTD 2019Q3 2020 Canadian Pharmaceutical Net Revenues of $5,470,569 increased by 14% versus Q3 2019YTD 2020 Canadian Pharmaceutical...
BioSyent Schedules Q3 and YTD 2020 Earnings Release for November 26, 2...
BioSyent Schedules Q3 and YTD 2020 Earnings Release for November 26, 2020 MISSISSAUGA, Ontario, Nov. 17, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2020 on Thursday, November 26, 2020. A presentation on the Company’s third quarter and year-to-date 2020 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”...
Biosyent Announces Launch of New FeraMAX® Pd Therapeutic 150
Biosyent Announces Launch of New FeraMAX® Pd Therapeutic 150 MISSISSAUGA, Ontario, Nov. 05, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce the launch of FeraMAX® Pd Therapeutic 150, the first new product incorporating FeraMAX® Pd, a new oral iron supplement delivery system, by its subsidiary BioSyent Pharma Inc. in Canada. The launch of FeraMAX® Pd Therapeutic 150 is yet another milestone in the innovation history of FeraMAX® and deepens BioSyent’s commitment to the management of iron deficiency and iron deficiency anemia in Cana...
Biosyent annonce le lancement du nouveau FeraMAX(MD) Pd Thérapeutique ...
Biosyent annonce le lancement du nouveau FeraMAX(MD) Pd Thérapeutique 150 MISSISSAUGA, Ontario, 05 nov. 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent », « la Société », Bourse de croissance : RX) a le plaisir d’annoncer le lancement de FeraMAXMD Pd Thérapeutique 150, le premier nouveau produit intégrant FeraMAXMD Pd, un nouveau système de libération orale de supplément de fer, par sa filiale BioSyent Pharma Inc. au Canada. Le lancement de FeraMAXMD Pd Thérapeutique 150 est un nouveau jalon dans l’histoire novatrice de FeraMAXMD et confirme l’engagement de BioSyent dans la prise en ch...
BioSyent Named to the Growth List Ranking of Canada’s Fastest-Growing ...
BioSyent Named to the Growth List Ranking of Canada’s Fastest-Growing Companies for Eighth Consecutive Year MISSISSAUGA, Ontario, Oct. 15, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it has been included in the 32nd annual Growth List, the definitive ranking of Canada’s Fastest-Growing Companies by Canadian Business and Maclean’s. The Growth List (formerly the Growth 500) ranks Canadian companies based on five-year revenue growth. Results of the annual ranking are published in a special print issue of Canadian Business with Maclean’s ma...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.